Serum levels of sFas and sFasL in subjects with type 2 diabetes - the impact of arterial hypertension

• Authors: Nikolay Stoynev , Krassimir Kalinov , Georgi Kirilov , Tsvetalina Tankova
• Languages of publication: EN

Abstracts

EN

Keywords

EN

sFas; sFasL; Hemodialysis; Diabetes; Prediabetes; Hypertension

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 9
• Issue: 5
• Pages: 704-708

Dates

published

1 - 10 - 2014

online

31 - 7 - 2014

Contributors

author

Nikolay Stoynev

author

Krassimir Kalinov

• New Bulgarian University, Sofia, 1618, Bulgaria

author

Georgi Kirilov

• Clinical Center of Endocrinology, Medical University, Sofia, 1431, Bulgaria

author

Tsvetalina Tankova

• Clinical Center of Endocrinology, Medical University, Sofia, 1431, Bulgaria

References

• [1] Nelson RG, Knowler RG, Petit DJ, Bennett PH. Kidney disease in diabetes. Diabetes in America. 2nd edn. Bethesda, MD: National Institutes of Health; 1995. Report No.95-1468. pp349–400
• [2] Rachmani R, Ravid M Risk factors for nephropathy in type 2 diabetes mellitus. Compr Ther. 1999 Jun–Jul;25(6–7):366–369 http://dx.doi.org/10.1007/BF02944283[Crossref]
• [3] Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al.: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J. 2007 Jan;28(1):88–136
• [4] Bennett MR Apoptosis in the cardiovascular system. Heart 2002; 87(5): 480–487 http://dx.doi.org/10.1136/heart.87.5.480[Crossref]
• [5] Cosson E, Brinquier AF, Paries J, Guillot R, Vaysse J, Attali JR, et al. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance. Diabetes Metab 2005; 31(1): 47–54 [Crossref]
• [6] Midis GP, Shen Y, Owen-Schaub LB Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996; 56(17):3870–3874
• [7] Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, et al.; ACTFAST investigators. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):168–174. Epub 2006 Oct 19 [WoS][Crossref]
• [8] García-Unzueta MT, Pesquera C, Calzada E, De la Mora A, Muñoz P, Llorca J, et al. Blood-soluble Fas levels are increased in type 2 diabetic patients with peripheral vascular disease. Horm Metab Res. 2006 Oct;38(10):673–677 http://dx.doi.org/10.1055/s-2006-954585[Crossref]
• [9] Masse M, Hébert MJ, Troyanov S, Vigneault N, Sirois I, Madore F. Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients. Nephrol Dial Transplant. 2002 Mar;17(3):485–491 http://dx.doi.org/10.1093/ndt/17.3.485[Crossref]
• [10] Troyanov S, Hébert MJ, Masse M, Vigneault N, Sirois I, Madore F Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis. 2003 May;41(5):1043–1051 http://dx.doi.org/10.1016/S0272-6386(03)00202-6[Crossref]
• [11] Hébert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore F. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis. 2001 Dec;38(6):1271–1276 http://dx.doi.org/10.1053/ajkd.2001.29224[Crossref]
• [12] Tomiyama C, Higa A, Dalboni MA, Cendoroglo M, Draibe SA, Cuppari L, et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant. 2006 Sep;21(9):2464–71. Epub 2006 May 30 http://dx.doi.org/10.1093/ndt/gfl291[Crossref]
• [13] World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. Geneva; 2006
• [14] Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.: The Task Force for the Management of Arterial Hypertension of the European Society for Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28:1462–1536
• [15] Kumar H, Mishra M, Bajpai S, Pokhria D, Arya AK, Singh RK, et al. Correlation of insulin resistance, beta cell function and insulin sensitivity with serum sFas and sFasL in newly diagnosed type 2 diabetes. Acta Diabetol. 2013 Aug;50(4):511–518 http://dx.doi.org/10.1007/s00592-011-0307-8[Crossref][WoS]
• [16] Mahfouz MH, Emara IA, Omar GA Biomarkers of Oxidative DNA Damage and Soluble Fas/Fas Ligand in Type 2 Diabetic Patients. American Journal of Applied Sciences 2012; 9(4):450–458 http://dx.doi.org/10.3844/ajassp.2012.450.458[Crossref]
• [17] Protopsaltis T, Kokkoris S, Nikolopoulos G, Spyropoulou P, Katsaros T, Salvanos L, et al. Correlation between increased serum sFas levels and microalbuminuria in type 1 diabetic patients. Med Princ Pract 2007; 16(3): 222–225 http://dx.doi.org/10.1159/000100394[Crossref][WoS]
• [18] Guillot R, Brinquier AF, Porokhov B, Guillausseau PJ, Feldmann G Increased levels of soluble Fas in serum from diabetic patients with neuropathy. Diabetes Metab 2001; 27(3): 315–321
• [19] Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2009 Jan;4(1):62–70. Epub 2008 Dec 10 http://dx.doi.org/10.2215/CJN.03010608[WoS][Crossref]
• [20] Baba K, Minatoguchi S, Sano H, Kagawa T, Murata I, Takemura G, et al. Involvement of apoptosis in patients with diabetic nephropathy: A study on plasma soluble Fas levels and pathological findings. Nephrology (Carlton). 2004 Apr;9(2):94–99 http://dx.doi.org/10.1111/j.1440-1797.2004.00238.x[Crossref]
• [21] Tankova T. Assessment of overall individual risk of diabetes. Dissertation, 2012
• [22] Tamakoshi A, Suzuki K, Lin Y, Ito Y, Yagyu K, Kikuchi S, et al.; JACC Study Group. Relationship of sFas with metabolic risk factors and their clusters. Eur J Clin Invest. 2010 Jun;40(6):527–533 http://dx.doi.org/10.1111/j.1365-2362.2010.02293.x[WoS][Crossref]
• [23] Karthikeyan VJ, Lip GY, Baghdadi S, Lane DA, Beevers DG, Blann AD. Soluble Fas and Fas ligand in pregnancy: influence of hypertension. Angiology. 2012 Jan;63(1):35–38 http://dx.doi.org/10.1177/0003319711406901[WoS][Crossref]
• [24] Bayram M, Taskaya A, Bagriacik EU, Ilhan MN, Yaman M The effect of maternal serum sFAS/sFASL system on etiopathogenesis of preeclampsia and severe preeclampsia. J Matern Fetal Neonatal Med. 2012 Aug 22. [Epub ahead of print]
• [25] Okura T, Watanabe S, Jiang Y, Nakamura M, Takata Y, Yang ZH, et al. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 2002 May;20(5):895–898 http://dx.doi.org/10.1097/00004872-200205000-00024[Crossref]
• [26] Cross DS, McCarty CA, Hytopoulos E, Beggs M, Nolan N, Harrington DS, et al. Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts. Curr Med Res Opin. 2012 Nov;28(11):1819–1830 http://dx.doi.org/10.1185/03007995.2012.742878[WoS][Crossref]

Identifiers

DOI

10.2478/s11536-013-0318-7